EDOR®, Emotra’s method, is at the beginning of its initial commercialisation phase. Emotra’s success will strongly depend on the Company’s ability to gain acceptance for the concept at academically prestigious clinics in Sweden and around the world.
This work on gaining acceptance began at the end of 2012 and it has continued since then. A broad international clinical multicentre study, EUDOR-A, with more than 1 500 patients tested and followed up, was initiated 2014 and finalized in March 2017. After a consensus meeting was held in Rome, March 29-30, the company took the decision to launch EDOR® to psychiatric specialists in Europe.
When these internationally leading clinics are satisfied and prepared to openly act as ambassadors in support of our method, the groundwork for a wider penetration of first the Swedish, then international markets will be laid.
A number of educational/training courses are held in different European countries during 2017 but according to plans the number of courses will increase significantly during 2018. The first courses have been organized as national events but the idea is to make them more and more as local courses in different European cities.
Development and CE-marking of the product itself is complete. Patent has been approved in Sweden and patent application has been field in within EU, US, Canada and Japan. The measurement curves from testing were previously analysed manually. Work with automating this analysis stage has come so far that a significant part of this analysis work can now be carried out by computer. Our continued software development will increase the method’s capacity.